Abstract:The four major comments of muscle wasting disease are cachexia, sarcopenia, malnutrition and congenital.1, 2 Of these, the most common is sarcopenia.3-7 Since sarcopenia is a clinical situation which causes various adverse outcomes, including immobility, falls, disability and death in older people 8-13, the importance of recognizing and treating sarcopenia has been recognized by providing an ICD-10 code for sarcopenia. Since the publication of the European Working Group consensus paper on sarcopenia in older persons,14 a number of other definitions have been published.15-18 All these definitions have stressed that sarcopenia should be defined as a loss of muscle function associated with a loss of muscle mass.19-21 This change in definition was necessitated by the recognition that muscle quality and, therefore, muscle performance were not directly related to muscle mass.22 Two factors appear to be responsible for this, viz the fact that sarcopenia is a neuromuscular junction disease23, 24 and the infiltration of fat into muscle during the ageing process.25, 26 The measurement of muscle mass has classically been done by anthropomorphic measures or dual energy x-ray absorptiometry.27 However, ultrasound, bioelectrical impedance, computed tomography, and magnetic resonance imaging have also been used. Goodman et al.,28 utilizing the NHANES data, suggested that Body Mass Index (BMI) is a reasonable proxy as a skeletal muscle index. Yu et al.29 utilized equations using BMI, weight, and age and showed that these are excellent predictive equations for skeletal muscle mass. A recent review of methods to assess sarcopenia found that for epidemiological studies, bioelectrical impedance for measuring muscle mass coupled with either gait speed or grip dynamometry were the most simple methods to identify sarcopenia based on the modern definitions.30 Recently it was shown that the questions used in the FRAX as part of diagnosis fracture risk had excellent specificity and sensitivity in recognizing risk when used without measuring bone mineral density.31 This raised the possibility that persons with sarcopenia could be identified by a simple questionnaire. This led to the development of SARC-F as a simple questionnaire to rapidly diagnose sarcopenia (Table 1).32, 33 Cao et al.34 showed that SARC-F was associated with poor physical performance, grip strength, and hospitalization in the previous 2 years. Woo et al.35 showed that SARC-F has excellent specificity when identifying persons with sarcopenia diagnosed by either the European or Asian working group definitions. Further, the Hong Kong group showed that SARC-F had similar predictive value for walking speed, physical limitation, hospitalization, and mortality as the Foundation of the National Institutes of Health and four other consensus definitions for sarcopenia.36 Woo et al.37 then showed that it could be used prospectively to successfully screen for sarcopenia. Malmstrom et al.38 showed that the SARC-F was a valid tool in three populations viz the Baltimore Longitudinal study, the African American Cohort in St. Louis, and the NHANES population. Sarcopenia is a major component of physical frailty in older persons.39 The simple FRAIL score has been shown to be a valid measure for detecting frailty.40-42 Between 40 and 70% of persons who are frail are also sarcopenic.37, 43 Thus, it makes sense to screen for both frailty and sarcopenia in older individuals as is done in the Rapid Geriatric Assessment (RGA).44 In addition, middle aged persons with diabetes mellitus,45-47 chronic obstructive pulmonary disease,48, 49 and hip fracture50, 51 are at high risk of having sarcopenia and therefore should be screened. The accumulating evidence shows that sarcopenia could be alleviated by resistance exercise,52-55 leucine enriched essential amino acids,56-58 and vitamin D.59 New promising drugs for sarcopenia are in development. 59 Given that we have a successful treatment which enhances outcome for sarcopenia, it would seem that utilizing the SARC-F, which takes under 15 s to do, to screen older persons and those with specific diseases with a high propensity to become sarcopenic, is an imminently sensible approach to prevent disability and hospitalization in older persons. The importance of recognizing and treating sarcopenia has been recognized by providing an ICD-10 code for sarcopenia. This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1QHP28716 Geriatrics Workforce Enhancement Program for $832 079. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government. The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia, and Muscle (von Haehling S, Morley JE, Coats AJS, Anker SD). Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia, and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8. None declared.

The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates

International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management

On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank

New Perspectives for Low Muscle Mass Quantity/Quality Assessment in Probable Sarcopenic Older Adults: An Exploratory Analysis Study

Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium

Rapid Screening for Sarcopenia

Sarcopenia and poor nutritional status in older adults

Sarcopenia: an overview

Sarcopenia With Limited Mobility: An International Consensus

Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management

The impact of sarcopenic obesity on inflammation, lean body mass, and muscle strength in elderly women

Identifying risk factors for pre-sarcopenia in early middle-age

RISK OF SARCOPENIA AND ASSOCIATED FACTORS IN HOSPITALIZED OLDER ADULTS WITH CARDIOVASCULAR DISEASE

Sarcopenia: revised European consensus on definition and diagnosis

Diagnostic Criteria and Measurement Techniques of Sarcopenia: A Critical Evaluation of the Up-to-Date Evidence

Factors associated with sarcopenia: A cross-sectional analysis using UK Biobank

1878 Sarcopenia screening in older community-dwelling adults: findings from Southampton Longitudinal Study of Ageing (SaLSA)

Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study

The Copenhagen Sarcopenia Study: lean mass, strength, power, and physical function in a Danish cohort aged 20–93 years